Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Navigating the Wild West of COVID-19 antibody tests

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

April 10, 2020 11:45 PM UTC
Updated on Apr 11, 2020 at 1:38 AM UTC

The expectation that widespread COVID-19 antibody testing will be a cornerstone for reopening society has prompted a speedy, hands-off regulatory approach. But reports of poor performance by marketed tests suggest moving too quickly could result in individual and public health decisions that are based on unreliable results.

Dodging that bullet will require centralized resources, including broad access to the large numbers of patient samples needed to stringently validate the assays...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article